IPRAX

Indications

• Maintenance treatment of chronic obstructive pulmonary disease (COPD)
• Reversible airways obstruction in asthma
• Rhinorrhea associated with allergic and non-allergic rhinitis

Dosage

Children: For inhalation: Child 1 month

Adults: For inhalation: 20–40 micrograms 3–4 times a day. For intranasal administration: Apply 2–3 drops 2–3 times a day into each nostril.

Mechanism of action

Ipratropium bromide acts as a competitive antagonist of acetylcholine at muscarinic receptors. This inhibition prevents bronchoconstriction and promotes bronchodilation, thereby easing airflow in obstructive airway diseases. It primarily affects M1 and M3 muscarinic receptors in the airway smooth muscle and secretory glands, reducing mucus secretion and aiding ventilation.

Pharmacodynamics

The onset of action for ipratropium bromide typically occurs within 30 to 60 minutes after inhalation, with peak effects observed at this time. Its bronchodilatory effects can last for approximately 3 to 6 hours, making it suitable for multiple doses throughout the day. The drug is less effective than beta-agonists in producing bronchodilation but has a complementary role in therapy, especially for patients with chronic conditions requiring long-term management.

Pharmacokinetics

Ipratropium bromide is administered via inhalation, leading to localized action in the lungs with minimal systemic absorption. The systemic bioavailability is low, resulting in a reduced incidence of systemic side effects. It undergoes hepatic metabolism, with metabolites excreted primarily in the urine. The elimination half-life varies but is generally around 2 hours, allowing for flexible dosing intervals. The maximal effect is usually achieved within an hour post-administration.

Adverse effects

• dizziness
• epistaxis
• dry mouth
• nausea

Interactions

• beta2 agonists

Precautions

• Avoid spraying near eyes
• Patients with convulsive disorders should use with caution

Pregnancy

Ipratropium bromide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a healthcare provider for individual assessment.

Breast-feeding

Ipratropium bromide is excreted in breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

• Inhalation aerosol: 20-40 micrograms per actuation
• Nebulised solution: 250 micrograms per dose
• Nasal spray: 20 micrograms per actuation

Indications

• Adjustment of pH in pharmaceutical formulations
• Facilitation of drug absorption
• Used in sterile preparations

Dosage

Children: Refer to specific product guidelines for dosing information, as hydrochloric acid is typically used in a controlled setting based on formulation requirements.

Adults: Refer to specific product guidelines for dosing information, as hydrochloric acid is typically used in a controlled setting based on formulation requirements.

Mechanism of action

Hydrochloric acid dissociates in aqueous solution to release hydrogen ions (H+), leading to a decrease in pH. This acidic environment promotes the activation of pepsinogen to pepsin, an enzyme essential for protein digestion. Additionally, the acidity aids in the absorption of certain minerals and drugs that require an acidic environment for optimal bioavailability.

Pharmacodynamics

The primary pharmacodynamic action of hydrochloric acid is the maintenance of gastric acidity, which is essential for normal digestive processes. The acidic environment helps in denaturing proteins, activating digestive enzymes, and providing a barrier against pathogenic microorganisms. Its effects can influence the absorption and efficacy of various medications, particularly those that are pH-dependent.

Pharmacokinetics

Hydrochloric acid does not undergo significant systemic absorption when used in its normal contexts, as it acts locally within the gastrointestinal tract. The amount of hydrochloric acid produced by the stomach varies with food intake and physiological needs. It is secreted by parietal cells in the gastric mucosa, and its secretion is regulated by neural, hormonal, and local factors. The half-life of hydrochloric acid is not applicable as it is continuously produced and neutralized within the gastrointestinal tract.

Contra-indications

• Hypersensitivity to hydrochloric acid or any of its components
• Severe renal impairment
• Active gastrointestinal bleeding

Adverse effects

• Abdominal pain
• Diarrhea
• Nausea
• Vomiting
• Esophageal irritation
• Gastric mucosal irritation
• Electrolyte imbalances

Interactions

• May interact with alkaline substances, potentially neutralizing hydrochloric acid
• Caution with antacids as they may affect the efficacy of hydrochloric acid

Precautions

• Use with caution in patients with a history of gastritis or gastric ulcers
• Monitor electrolytes in prolonged use
• Use cautiously in patients with respiratory conditions due to potential aspiration risks

Pregnancy

Hydrochloric acid is classified as a category C drug. Use during pregnancy only if clearly needed and the potential benefits justify the risks to the fetus.

Breast-feeding

There is limited data on the excretion of hydrochloric acid in human milk. Use with caution during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight and heat. Ensure the container is tightly closed.

Formulations

• Oral solutions
• Injectable forms
• Tablets

Dosage

Children: Refer to specific guidelines for pediatric dosing; consult the BNF for Children for accurate dosage information.

Adults: Refer to specific guidelines for use; dosage may vary based on the context of use.

Mechanism of action

Hydroxide ions act primarily as bases, neutralizing acids to form water and salts. They participate in various biochemical pathways, including selenium metabolism and the degradation of reactive oxygen species. Hydroxide can influence enzyme activity and stability by altering the pH of the environment, thereby affecting metabolic reactions.

Pharmacodynamics

Hydroxide ions can impact biological processes by changing the local pH, which influences enzyme activity, ion transport, and the solubility of other compounds. Their ability to neutralize acids can help regulate physiological pH, contributing to homeostasis in living organisms.

Pharmacokinetics

As an inorganic ion, hydroxide does not undergo traditional pharmacokinetic processes like absorption, distribution, metabolism, or excretion. Instead, it is rapidly equilibrated in biological fluids and participates in acid-base reactions, having immediate effects on the local environment.

Pregnancy

There is limited information regarding the use of hydroxide during pregnancy. Consult a healthcare professional for advice.

Breast-feeding

Limited data is available on the excretion of hydroxide in breast milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Chronic obstructive pulmonary disease (COPD)
• Asthma
• Acute bronchospasm
• Bronchospasm associated with COPD

Dosage

Children: For children aged 6 to 12 years, the recommended dose is 250 micrograms via inhalation, up to three times a day. For children under 6 years, dosing should be determined by a healthcare professional, and the use of ipratropium in this age group requires careful consideration.

Adults: The usual adult dose for ipratropium is 500 micrograms via inhalation, administered up to four times a day. The maximum dose should not exceed 2000 micrograms in 24 hours.

Mechanism of action

Ipratropium works by inhibiting the action of acetylcholine on muscarinic receptors in the bronchial smooth muscle, leading to bronchodilation. It prevents bronchoconstriction and reduces mucus secretion in the airways, thus improving airflow and decreasing respiratory distress.

Pharmacodynamics

The onset of action for ipratropium is typically within 15 minutes, with a peak effect occurring around 1 to 2 hours after administration. Its effect can last for approximately 4 to 6 hours. It is more effective in patients with COPD than in those with asthma, though it can be used in both conditions. The drug is sometimes used in conjunction with beta-agonists to enhance bronchodilation.

Pharmacokinetics

Ipratropium is poorly absorbed from the gastrointestinal tract and has minimal systemic bioavailability when inhaled. It has a half-life of approximately 1.5 hours. The drug is primarily excreted unchanged in the urine. Its pharmacokinetic profile supports its use in inhaled formulations, as it provides localized effects with reduced systemic side effects.

Contra-indications

• Hypersensitivity to ipratropium or any component of the formulation
• Acute exacerbation of bronchospasm

Adverse effects

• Dry mouth
• Cough
• Headache
• Nausea
• Dizziness
• Pharyngeal irritation

Interactions

• Clozapine: Unknown (additive effect)
• Beta 2-agonists: Unknown (increases risk of glaucoma)
• Second-generation antipsychotics: Unknown (additive effect)

Precautions

• Use with caution in patients with glaucoma
• Patients with prostatic hyperplasia or bladder neck obstruction should be monitored closely
• Caution in patients with cardiovascular disorders

Pregnancy

Ipratropium is classified as category B. Limited data suggest it is not expected to cause harm to the fetus.

Breast-feeding

Ipratropium is excreted in breast milk but is not expected to harm a nursing infant. Consider benefits versus risks.

Storage

Store in a cool, dry place, away from light. Do not freeze.

Formulations

• Inhalation solution
• Aerosol inhaler
• Nasal spray